Bioventus Inc.
BVS · XNASCIK 1665988fmd_1VMFVCSQDV6RNYJ47807AZ00Z0Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2019 to Sep 26, 2026, 28 periods
Latest annual · FY2025
Millions- Total revenues
- 568
- Gross profit
- 388
- Operating income
- 54
- Net income
- 23
- Free cash flow
- 72
Latest quarter · Q3 FY2026
Millions- Total revenues
- 142
- Gross profit
- 97
- Operating income
- 10
- Net income
- 6
- Free cash flow
- 20
Daily close · BVSIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions11.00 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +3.5%
- Revenue, 5 yearsFY2020 to FY2025
- +12.1%
- Net income, 5 yearsFY2020 to FY2025
- +6.7%
Bioventus Inc. (BVS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $568.1 million | $573.3 million | -0.9% | 10-K 2026-03-05 · proof |
| Gross profit | $388.2 million | $388.2 million | 0% | 10-K 2026-03-05 · proof |
| Operating income | $54 million | -$15.2 million | 10-K 2026-03-05 · proof | |
| Net income | $22.7 million | -$36.1 million | 10-K 2026-03-05 · proof | |
| Cash from operating activities | $74.7 million | $38.8 million | +92.5% | 10-K 2026-03-05 · proof |
| Free cash flow | $72.1 million | $37.8 million | +90.8% | 10-K 2026-03-05 · proof |
| Total assets | $683.6 million | $728 million | -6.1% | 10-K 2026-03-05 · proof |
| Total liabilities | $455.1 million | $542.4 million | -16.1% | 10-K 2026-03-05 · proof |
| Cash and cash equivalents | $51.2 million | $41.6 million | +23.2% | 10-K 2026-03-05 · proof |
| Total debt | $294 million | $335.6 million | -12.4% | 10-K 2026-03-05 · proof |
- What was Bioventus Inc. (BVS)'s revenue in fiscal 2025?
- Bioventus Inc. (BVS) reported revenue of $568.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $573.3 million the year before (-0.9%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Bioventus Inc. (BVS)'s gross profit in fiscal 2025?
- Bioventus Inc. (BVS) reported gross profit of $388.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $388.2 million the year before (0%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Bioventus Inc. (BVS)'s operating income in fiscal 2025?
- Bioventus Inc. (BVS) reported operating income of $54 million for fiscal 2025 (the year ended Dec 31, 2025), against -$15.2 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Bioventus Inc. (BVS)'s net income in fiscal 2025?
- Bioventus Inc. (BVS) reported net income of $22.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$36.1 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Bioventus Inc. (BVS)'s cash from operating activities in fiscal 2025?
- Bioventus Inc. (BVS) reported cash from operating activities of $74.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $38.8 million the year before (+92.5%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Bioventus Inc. (BVS)'s free cash flow in fiscal 2025?
- Bioventus Inc. (BVS) reported free cash flow of $72.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $37.8 million the year before (+90.8%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Bioventus Inc. (BVS)'s total assets?
- As of Dec 31, 2025, Bioventus Inc. (BVS) reported total assets of $683.6 million, against $728 million a year earlier (-6.1%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Bioventus Inc. (BVS)'s total liabilities?
- As of Dec 31, 2025, Bioventus Inc. (BVS) reported total liabilities of $455.1 million, against $542.4 million a year earlier (-16.1%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Bioventus Inc. (BVS)'s cash and cash equivalents?
- As of Dec 31, 2025, Bioventus Inc. (BVS) reported cash and cash equivalents of $51.2 million, against $41.6 million a year earlier (+23.2%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What is Bioventus Inc. (BVS)'s total debt?
- As of Dec 31, 2025, Bioventus Inc. (BVS) reported total debt of $294 million, against $335.6 million a year earlier (-12.4%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BVS&period_type=annual&limit=5"Information only, not investment advice.